Fresenius SE & Co KGaA (FRA:FRE) Given Average Rating of “Buy” by Brokerages

Fresenius SE & Co KGaA (FRA:FRE) has earned an average rating of “Buy” from the sixteen analysts that are presently covering the stock, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, five have assigned a hold recommendation and ten have given a buy recommendation to the company. The average 1 year price target among analysts that have covered the stock in the last year is €50.68 ($59.62).

A number of research firms have recently issued reports on FRE. Berenberg Bank set a €59.50 ($70.00) target price on shares of Fresenius SE & Co KGaA and gave the company a “buy” rating in a research note on Thursday, July 30th. UBS Group set a €47.00 ($55.29) price target on shares of Fresenius SE & Co KGaA and gave the company a “neutral” rating in a report on Friday, June 26th. Goldman Sachs Group set a €47.00 ($55.29) price target on shares of Fresenius SE & Co KGaA and gave the company a “buy” rating in a report on Thursday, July 30th. Morgan Stanley set a €49.00 ($57.65) price target on shares of Fresenius SE & Co KGaA and gave the company a “buy” rating in a report on Tuesday, September 1st. Finally, JPMorgan Chase & Co. reissued a “buy” rating on shares of Fresenius SE & Co KGaA in a report on Thursday, September 3rd.

FRA FRE opened at €39.82 ($46.85) on Thursday. Fresenius SE & Co KGaA has a twelve month low of €60.16 ($70.78) and a twelve month high of €80.00 ($94.12). The firm has a 50-day simple moving average of €39.68 and a 200 day simple moving average of €40.22.

Fresenius SE & Co KGaA Company Profile

Fresenius SE & Co KGaA, a health care group, provides products and services for dialysis, hospitals, and outpatient medical care worldwide. The company operates through four segments: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed. The Fresenius Medical Care segment offers products and services for patients with chronic kidney failure.

Featured Story: S&P/TSX Index

Analyst Recommendations for Fresenius SE & Co KGaA (FRA:FRE)

Receive News & Ratings for Fresenius SE & Co KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius SE & Co KGaA and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply